Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Nov 9;10:1758835918808509. doi: 10.1177/1758835918808509

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2018

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Schematic representation of the approved and novel SMIs for breast cancer treatment discussed in this review.

Approved SMIs for CDK4/6 are represented by palbociclib, ribociclib and abemaciclib, and the PARP inhibitor, olaparib. Veliparib and talazoparib are novel SMIs against PARP, while buparlisib and alpelisib are novel SMIs, targeting PI3K.

CDK4/6, cyclin-dependent kinase 4 and 6; PARP, poly (adenosine diphosphate-ribose) polymerase; PI3K, phosphoinositide 3-kinase; SMI, small molecule inhibitor.